SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 5,304 Shares

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the transaction, the chief financial officer now owns 189,319 shares in the company, valued at $2,633,427.29. The trade was a 2.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, November 18th, Anshul Maheshwari sold 2,439 shares of SI-BONE stock. The shares were sold at an average price of $12.68, for a total value of $30,926.52.

SI-BONE Stock Performance

Shares of SI-BONE stock traded down $0.15 during trading on Monday, hitting $14.12. 231,586 shares of the stock were exchanged, compared to its average volume of 251,762. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The company has a fifty day moving average price of $13.58 and a 200-day moving average price of $14.14. The stock has a market capitalization of $592.16 million, a price-to-earnings ratio of -15.35 and a beta of 1.16. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $21.64.

Analyst Ratings Changes

Several brokerages recently commented on SIBN. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 target price on shares of SI-BONE in a research report on Wednesday, November 20th. Truist Financial increased their price target on shares of SI-BONE from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $23.00.

Institutional Investors Weigh In On SI-BONE

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its holdings in shares of SI-BONE by 29.0% during the 3rd quarter. Jane Street Group LLC now owns 77,359 shares of the company's stock worth $1,081,000 after buying an additional 17,410 shares in the last quarter. Millrace Asset Group Inc. acquired a new position in SI-BONE during the third quarter worth about $1,056,000. Champlain Investment Partners LLC lifted its holdings in shares of SI-BONE by 14.7% in the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company's stock worth $39,145,000 after acquiring an additional 358,821 shares during the last quarter. Impax Asset Management Group plc boosted its stake in shares of SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company's stock valued at $10,604,000 after purchasing an additional 221,604 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of SI-BONE by 22.8% during the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company's stock valued at $25,685,000 after purchasing an additional 368,637 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.